Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy
Roni Tamari, Ioannis Politikos, David A. Knorr, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 6, pp. 577-585
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
Robert Stuver, Gunjan L. Shah, Neha Korde, et al.
Cancer Cell (2022) Vol. 40, Iss. 6, pp. 590-591
Open Access | Times Cited: 86
Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy
Kitsada Wudhikarn, Miguel‐Angel Perales
Bone Marrow Transplantation (2022) Vol. 57, Iss. 10, pp. 1477-1488
Open Access | Times Cited: 80
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
Nico Gagelmann, Francesco Passamonti, Christine Wolschke, et al.
Haematologica (2021) Vol. 107, Iss. 8, pp. 1840-1849
Open Access | Times Cited: 67
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting
Moshe Mittelman, Ori Magen, Noam Barda, et al.
Blood (2021) Vol. 139, Iss. 10, pp. 1439-1451
Open Access | Times Cited: 63
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review
Vanessa Piechotta, Sibylle C. Mellinghoff, Caroline Hirsch, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 5
Open Access | Times Cited: 32
SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study
Joshua A. Hill, Michael J. Martens, Jo‐Anne H. Young, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101983-101983
Open Access | Times Cited: 21
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study
Joshua A. Hill, Michael J. Martens, Jo‐Anne H. Young, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 2, pp. 542-554
Closed Access | Times Cited: 8
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
Firas El Chaer, Jeffery J. Auletta, Roy F. Chemaly
Blood (2022) Vol. 140, Iss. 7, pp. 673-684
Open Access | Times Cited: 28
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis
Chenghao Ge, Kelei Du, Mingjie Luo, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 25
Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
M. Veronica Dioverti, Zeinab El Boghdadly, Zainab Shahid, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 12, pp. 810-821
Open Access | Times Cited: 25
Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy
María Stefania Infante, David Nemirovsky, Sean M. Devlin, et al.
Transplantation and Cellular Therapy (2023) Vol. 30, Iss. 1, pp. 116.e1-116.e12
Open Access | Times Cited: 14
SARS‐CoV‐2 vaccine response in CAR T‐cell therapy recipients: A systematic review and preliminary observations
Muhammad Abbas Abid, Muhammad Bilal Abid
Hematological Oncology (2021) Vol. 40, Iss. 2, pp. 287-291
Closed Access | Times Cited: 28
Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study
Lu Yang, Cristina Costales, Muthukumar Ramanathan, et al.
Journal of Clinical Virology (2022) Vol. 153, pp. 105217-105217
Open Access | Times Cited: 20
Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients – targeting the target antigen
Bradley Uyemura, Muhammad Abbas Abid, Elizabeth Suelzer, et al.
Bone Marrow Transplantation (2022) Vol. 57, Iss. 11, pp. 1727-1731
Open Access | Times Cited: 20
COVID-19 and HSCT (Hematopoietic stem cell transplant)
Lynne Strasfeld
Best Practice & Research Clinical Haematology (2022) Vol. 35, Iss. 3, pp. 101399-101399
Open Access | Times Cited: 20
Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections
Natalia Egri, Hugo Calderón, Robert Martinez, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies
Antoni Ribas, Madhav V. Dhodapkar, Katie M. Campbell, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 6, pp. 562-567
Open Access | Times Cited: 26
Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination
Deniz Can Güven, Taha Koray Şahin, Serkan Akın, et al.
The Oncologist (2022) Vol. 27, Iss. 4, pp. e357-e361
Open Access | Times Cited: 17
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis
Εfstathia Liatsou, Ioannis Ntanasis‐Stathopoulos, Stavros Lykos, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2266-2266
Open Access | Times Cited: 10
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
Eleftheria Kampouri, Joshua A. Hill, M. Veronica Dioverti
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Closed Access | Times Cited: 10
Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell–Depleted Stem Cell Transplantation
Ok-Kyong Chaekal, Alexandra Gomez-Arteaga, Zhengming Chen, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 9, pp. 618.e1-618.e10
Open Access | Times Cited: 16
Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients
Bernice Oh, Nicole Tan, Ruklanthi de Alwis, et al.
Blood (2022) Vol. 140, Iss. 2, pp. 156-160
Open Access | Times Cited: 15
Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies
Cristina Bergamaschi, Maria Pagoni, Margherita Rosati, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 15
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era
Jonathan Bordat, Sébastien Maury, Mathieu Leclerc
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies
Maryam Noori, Shadi Azizi, Farhan Abbasi Varaki, et al.
International Immunopharmacology (2022) Vol. 110, pp. 109046-109046
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top